eltrombopag + placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Purpura, Thrombocytopenic, Idiopathic and Hepatitis C

Conditions

Purpura, Thrombocytopenic, Idiopathic and Hepatitis C

Trial Timeline

Feb 18, 2013 → Nov 22, 2018

NCT ID

NCT01762761

About eltrombopag + placebo

eltrombopag + placebo is a phase 3 stage product being developed by Novartis for Purpura, Thrombocytopenic, Idiopathic and Hepatitis C. The current trial status is completed. This product is registered under clinical trial identifier NCT01762761. Target conditions include Purpura, Thrombocytopenic, Idiopathic and Hepatitis C.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04797000	Phase 2	Active	May 25, 2021	Dec 9, 2026	Myelodysplastic Syndromes
NCT03603795	Phase 2	Active	Oct 11, 2018	Jul 30, 2026	Acute Myeloid Leukemia
NCT02446145	Phase 2	Terminated	May 1, 2015	Jan 25, 2023	Acute Myeloid Leukemia
NCT02093325	Phase 3	UNKNOWN	Mar 1, 2014	Aug 1, 2019	Solid Tumor
NCT01762761	Phase 3	Completed	Feb 18, 2013	Nov 22, 2018	Purpura, Thrombocytopenic, Idiopathic and Hepatitis C
NCT01880047	Phase 2	Completed	Feb 1, 2013	Oct 16, 2017	Immune Thrombocytopenia
NCT01440374	Phase 2	Completed	Sep 1, 2011	Dec 1, 2015	Thrombocytopaenia
NCT01000051	Phase 2	Completed	Feb 17, 2010	Apr 4, 2018	Thrombocytopenia

Competing Products

20 competing products in Purpura, Thrombocytopenic, Idiopathic and Hepatitis C

See all competitors

Product	Company	Stage	Hype Score
E5501	Eisai	Phase 1	33
E5501 + Drug: E5501	Eisai	Phase 1	33
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food	Eisai	Phase 1	33
Eltrombopag + Avatrombopag + Standard of care	Eisai	Phase 3	77
Placebo + Avatrombopag tablets	Eisai	Phase 2	52
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)	Eisai	Phase 2	52
10-mg dose of E5501 2G tablet + 10-mg dose of E5501 cyclodextrin oral solution + 10-mg dose of E5501-P21% powder + 10-mg dose of E5501 lipid-based oral	Eisai	Phase 1	33
AMG 531	Kyowa Kirin	Phase 2/3	65
Romiplostim (AMG-531)	Kyowa Kirin	Phase 2	52
Hetrombopag Olamine + matching placebo	Jiangsu Hengrui Medicine	Phase 3	77
Hetrombopag Olamine	Jiangsu Hengrui Medicine	Phase 1	33
Hetrombopag Olamine	Jiangsu Hengrui Medicine	Phase 1	33
MK-8723 + Matching Placebo	Merck	Phase 1	33
Eltrombopag	Novartis	Phase 2	52
eltrombopag	Novartis	Phase 2	52
Eltrombopag	Novartis	Pre-clinical	23
Eltrombopag	Novartis	Phase 3	77
Eltrombopag + IVIG infusion	Novartis	Phase 3	77
eltrombopag olamine (SB-497115-GR)	Novartis	Phase 3	77
Eltrombopag Tablets + Eltrombopag PfOS	Novartis	Phase 3	77

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved